Drug Database
BE

betamethasone dipropionate (DFD01 / DFD 01 / Sernivo)

✓ Approved

Encore Dermatology, Inc. · Steroids · Steroids

What is betamethasone dipropionate?

betamethasone dipropionate is a steroids developed by Encore Dermatology, Inc.. It is approved for therapeutic indications via topical.

Drug Profile

Brand NamesDFD01, DFD 01, Sernivo
CompanyEncore Dermatology, Inc.
Drug ClassSteroids, Small Molecule
RouteTopical
StatusApproved
Sources: ClinicalTrials.gov, Encore Dermatology, Inc.

Therapeutic Indications

betamethasone dipropionate is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Skin and subcutaneous tissue disordersPsoriasis✓ Approved

Related Research Articles

PubMedCureus2026-08-29

Two Cases of Posner-Schlossman Syndrome With the Detection of Human Herpesvirus 6 DNA in the Aqueous Humor.

Fukushima Atsuki A, Wakuda Hiroyuki H, Tabuchi Hitoshi H

Posner-Schlossman syndrome (PSS) is one of the disorders characterized by the acute elevation of intraocular pressure (IOP). Because cytomegalovirus (CMV), varicella-zoster virus (VZV), and herpes simplex virus (HSV) have been detected in the aqueous humor of patients with PSS, a viral etiology has long been suspected. We encountered two patients with PSS in whom a polymerase chain reaction (PCR) analysis of aqueous humor detected human herpesvirus 6 (HHV-6) DNA. Both patients presented with elevated IOP and anterior chamber inflammation. Treatment with topical betamethasone and topical ganciclovir resulted in the normalization of IOP and the resolution of anterior chamber inflammation. Previous reports have suggested an association between uveitis and HHV-6 infection. Therefore, HHV-6 may also play a role in the pathogenesis of Posner-Schlossman syndrome.

PMID 42666687
Read full article →
PubMedCardiovascular therapeutics2026-08-29

Uncovering Potential Druggable Targets in Coronary Atherosclerosis: A Proteome-Wide Mendelian Randomization Study With Cross-Platform and Experimental Validation.

Gao Da D, Lin Haiyan H, Wang Shengjie S, Wang Yanwei Y et al.

Coronary atherosclerosis (CA) is a leading cause of cardiovascular morbidity and mortality worldwide. This study is aimed at identifying candidate plasma proteins and potential therapeutic targets for CA. We performed a proteome-wide Mendelian randomization (MR) analysis using integrated protein quantitative trait loci (pQTLs) and genome-wide association study (GWAS) summary data. Forward two-sample MR was first performed using cis-pQTLs from the UK Biobank Pharma Proteomics Project (UKB-PPP), followed by reverse MR analysis to exclude potential reverse causality. Bayesian colocalization analysis was conducted to ensure that the associations between proteins and CA were driven by shared genetic variants. Summary-data-based MR (SMR) combined with HEIDI testing was used to prioritize proteins and eliminate linkage bias. Significant proteins were cross-referenced with a curated druggable genome to identify their potential therapeutic relevance. Cross-platform validation was performed using the SomaScan-based pQTL dataset from deCODE genetics. An oxidized low-density lipoprotein (ox-LDL)-induced human umbilical vein endothelial cell (HUVEC) injury model was used for the evaluation of prioritized proteins. Forward MR analysis using UKB-PPP cis-pQTL data identified 45 CA-associated proteins (23 protective, 22 risk-related; FDR < 0.05), with no reverse causality observed. Five proteins-PARP1, SDCCAG8, FST, FOLH1, and NCAN-were prioritized through MR (FDR < 0.05), colocalization analysis (PP.H4 > 0.50), and SMR analysis with HEIDI filtering (p_SMR < 0.05; p_HEIDI > 0.05). All five proteins were included in the druggable genome list, supporting their potential therapeutic relevance. PARP1 showed consistent associations across Olink and SomaScan platforms and was upregulated in an ox-LDL-induced HUVEC model as assessed by western blot. This study identified PARP1, SDCCAG8, FST, FOLH1, and NCAN as genetically prioritized candidate proteins for CA, with PARP1 showing the most consistent evidence across analyses. Further validation and mechanistic studies are warranted.

PMID 42666106
Read full article →
PubMedPharmacoepidemiology and drug safety2026-08-28

Corticosteroid Use and In-Hospital Mortality in Patients With Brain Abscess: A Target Trial Emulation.

Anno Takayuki T, Fukasawa Toshiki T, Kawakami Koji K

Corticosteroids are sometimes administered to patients with severe brain edema associated with brain abscess. However, no studies have used methods that appropriately account for time-varying covariates and immortal time to evaluate the impact of intravenous corticosteroid use on in-hospital mortality. Therefore, we aimed to address these limitations and estimate the impact on in-hospital mortality using a target trial emulation framework. We identified patients admitted with brain abscess, not caused by head trauma or neurosurgical interventions, from two large-scale hospital-based databases in Japan between 2014 and 2024. We compared two treatment strategies: Strategy 1 was initiation of intravenous dexamethasone or betamethasone administration within 7 days after admission and continuing for at least 3 consecutive days; Strategy 2 was no intravenous corticosteroid use throughout hospitalization. Using a clone-censor-weight approach, we estimated the 60-day in-hospital mortality. A total of 627 patients met the eligibility criteria. Overall, 34 patients (5.4%) died within 60 days. The estimated total effect of treatment strategy on 60-day all-cause in-hospital death was 4.8% (95% CI, 1.1-9.2) for Strategy 1, and 4.6% (95% CI, 2.9-6.6) for Strategy 2, corresponding to a risk ratio of 1.04 (95% CI, 0.26-2.08) and risk difference of 0.2% (95% CI, -3.3 to 4.3). No clear difference in 60-day in-hospital mortality between the two treatment strategies; however, the wide confidence intervals indicate that clinically important benefit or harm could not be excluded. This study's framework may guide future studies using more granular data.

PMID 42663102
Read full article →
PubMedRSC advances2026-08-27

Betamethasone-loaded poly(1,4-butylene carbonate) film: a potential material for repairing tympanic membrane perforations.

Wu Linrong L, Shen Yiming Y, Zhang Xiaoqin X, Yan Jiangyu J et al.

This study aimed to investigate the potential of poly(1,4-butylene carbonate) (PBC) films loaded with betamethasone for repairing tympanic membrane (TM) perforations. Drug-loaded PBC films were fabricated via a precise solvent casting method. Comprehensive characterization and biological assessments were conducted on the resultant films. In vitro assays demonstrated that the betamethasone-loaded PBC films possessed optimal physicochemical properties and significantly promoted cell viability. In vivo subcutaneous implantation studies revealed negligible hemolytic activity and confirmed the favorable biocompatibility and biodegradability of the composite films. Furthermore, a rat acute TM perforation model verified the superior morphological repair efficacy of the 1 wt% betamethasone-loaded PBC membrane. Collectively, these results highlight the potential of betamethasone-loaded PBC films as biomaterials for the morphological reconstruction of damaged tympanic membranes. Notably, all the observations in this work have come from evaluating only the structural repair of the TM; auditory functional tests, including ABR and tympanometry, have not been included, and we have made no claims regarding hearing recovery.

PMID 42657187
Read full article →
PubMedPharmaceuticals (Basel, Switzerland)2026-08-27

Etoricoxib-Betamethasone Combination Attenuates Inflammatory Nociception and Edema in Adjuvant-Induced Arthritis via Cytokine and Macrophage Axis Modulation.

Pérez-Urizar José J, Torres-Roque Irma I, Rangel-Ramírez Velia Verónica VV, Castillo-Enriquez Juan Pablo JP et al.

Background/Objectives: Acute inflammatory episodes demand rapid symptom control while limiting systemic exposure. We assessed whether co-therapy with the selective cyclooxygenase-2 (COX-2) inhibitor etoricoxib and the corticosteroid betamethasone provides antinociceptive and anti-edema activity in a rat model with complete Freund's adjuvant-induced arthritis (AIA). Methods: Male Wistar rats (n = 10/group) were allocated to seven groups: Intact, AIA disease control, indomethacin 5 mg/kg, etoricoxib 8 mg/kg, betamethasone 0.022 mg/kg, low-dose combination (4 + 0.011 mg/kg), and full-dose combination (8 + 0.022 mg/kg), administered orally once daily from Days 4 to 28. Paw edema, von Frey withdrawal thresholds, and clinical arthritis score were assessed longitudinally as area under the curve (AUC) values. Terminal joint tissues were profiled for cytokines, prostaglandin pathway mediators, and immune cell markers. Results: Both combinations reduced edema and improved mechanical thresholds. The full-dose combination exceeded either monotherapy regarding mechanical sensitivity and the arthritis index, consistent with additive activity. The low-dose combination matched full-dose monotherapies, consistent with a dose-reduction effect. Biomarker shifts indicated attenuated prostaglandin signaling and a pro-resolving cytokine balance. Conclusions: These findings support the further evaluation of etoricoxib-betamethasone co-therapy for acute inflammatory conditions.

PMID 42653732
Read full article →
PubMedPathogens (Basel, Switzerland)2026-08-27

Treatment Efficacy of Imidocarb Dipropionate in Saanen Goats Experimentally Infected with Babesia aktasi.

Ulucesme Mehmet Can MC, Ozubek Sezayi S, Aktas Munir M

Babesia aktasi is a recently discovered species that is highly prevalent in native goats in Türkiye's Mediterranean region. Although it does not induce clinical disease in local breeds, it causes severe illness in Saanen goats, manifesting with high fever, anemia, hemoglobinuria, and jaundice. Imidocarb dipropionate (IMDP) has been reported to be therapeutically effective against Babesia species. This study aimed to evaluate the therapeutic efficacy of IMDP and its ability to eliminate the parasite in experimentally infected Saanen goats. Twelve goats were assigned to treatment and control groups (n = 5 per group) and infected using fresh blood from two splenectomized donors. All goats developed clinical babesiosis, with parasitemia ranging from 3.8% to 22. Semi-nested PCR specific to B. aktasi was performed for 30 days post-treatment. Following treatment with IMDP (1.2 mg/kg), clinical signs resolved by the third and fourth days, and parasitemia became microscopically undetectable. However, one goat in the treatment group and four goats in the control group died shortly after infection. Hematological parameters (HCT, RBC, HB) decreased during infection but normalized in surviving animals. Notably, B. aktasi DNA remained detectable by PCR up to 30 days after treatment. These findings indicated that IMDP resolved clinical signs and eliminated microscopically detectable parasitemia; however, it may not completely eliminate the parasite at the molecular level in B. aktasi infections. The results of this study provide valuable information for optimizing therapeutic approaches and improving our understanding of treatment responses in new species B. aktasi.

PMID 42654770
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about betamethasone dipropionate